MedTrace Logo

Clinical Study of Propranolol Combined With Neoadjuvant Chemotherapy in Gastric Cancer

NCT04005365 · Status: UNKNOWN · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 78

Last updated 2019-11-26

No results posted yet for this study

Summary

At the cellular and animal level, we found that propranolol can inhibit the proliferation and invasion of gastric cancer cells. Further, we want to explore the efficacy and safety of propranolol in the treatment of gastric cancer patients.

Conditions

Interventions

DRUG

Propranolol

add propranolol in gastric cancer patients who need to receive preoperate chemotherapy

Sponsors & Collaborators

  • Xiangya Hospital of Central South University

    collaborator OTHER

  • Yijing He

    lead OTHER

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Max Age
75 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2019-11-20
Primary Completion
2020-06-01
Completion
2020-06-01

Countries

  • China

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04005365 on ClinicalTrials.gov